NCT06320405View on ClinicalTrials.gov

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2029

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Interventions
BIOLOGICAL

Axatilimab

Given IV

PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Paclitaxel

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

BIOLOGICAL

Retifanlimab

Given IV

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Incyte Corporation

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT06320405 - Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter